Special Medical Liaisons Are No Back Door To Off-Label Promotion - Experts
This article was originally published in The Gray Sheet
Specialized medical liaisons can help companies navigate scientific discussions on off-label product applications, but are not immune to government enforcement efforts when they cross the line, experts caution
You may also be interested in...
FDA draft guidance weighs in on web communications, saying that firms must answer off-label-information questions privately, even if the questions arise in a public online forum.
Stryker's biotech division and four former and current executives face charges of wire fraud, conspiracy, device misbranding and false statements related to the marketing of its OP-1 orthopedic bone growth biologic/device combination products
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.